Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

56 results about "Enzyme replacement therapy" patented technology

Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.

Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders

The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and / or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.
Owner:DUKE UNIV

Dose escalation enzyme replacement therapy for acid sphingomyelinase deficiency

To provide methods of treating a human subject having non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), and in certain embodiments, NPD subtype B.SOLUTION: A method for treating a human subject having an acid sphingomyelinase deficiency comprises: (a) a regimen for debulking an accumulated sphingomyelin substrate in the human subject including (i) administering an initial low non-toxic dose of an acid sphingomyelinase (ASM) to the human subject, and (ii) administering successively higher doses of ASM to the human subject and monitoring the subject for one or more adverse side effects after each successive dose as indicated by elevated bilirubin or a related adverse event; and (b) a maintenance regimen comprising administering a dose equal to or less than the highest dose tolerated by the subject as a maintenance dose for the subject.SELECTED DRAWING: None
Owner:MT SINAI SCHOOL OF MEDICINE +1

Pet tracer compounds for tracing alpha-galactosidase a and reaction intermediates, and methods of use

The present invention provides, among other things, novel tracers, compositions for tracking expression levels and in vivo activities of α -galactosidase A (α -Gal A) or a variant thereof. Those compounds specifically bind to α -galactosidase A. Use of those radiolabeled compounds for example in PET imaging, can monitor α -galactosidase A (α -Gal A) in a patient having Fabry disease after the patient receives an α -galactosidase A gene therapy or after an enzyme replacement therapy.
Owner:TAKEDA PHARMA CO LTD +5

FN3 domain-siRNA conjugates with enzyme replacement therapy

The present disclosure relates to compositions in combination with enzyme replacement therapy, such as siRNA molecules and FN3 domains conjugated thereto, as well as methods of making and using these compositions. Also disclosed is a method of treating a glycogen storage disease comprising administering a composition comprising a siRNA molecule and an FN3 domain conjugated thereto, and an enzyme replacement therapy (ERT) for treating the glycogen storage disease.
Owner:ARO BIOTHERAPEUTICS CO

Therapeutic adeno-associated virus for treating pompe disease with long term cessation of GAA enzyme replacement therapy

Disclosed herein are methods for the treatment of Pompe Disease comprising administering a recombinant AAV (rAAV) vector comprising a rAVV genome comprising a heterologous nucleic acid encoding an acid alpha-glucosidase (GAA) polypeptide operatively linked to a liver-specific promoter, wherein the subject is withdrawn or not administered enzyme replacement therapy (ERT).
Owner:ASKBIO INC +1

Immunosuppression therapy to mitigate immune responses against soluble alkaline phosphatase

The present disclosure features methods for treating neutralizing antibodies that reduce the efficacy of soluble alkaline phosphatase therapy (e.g., asfoenzyme alpha), which is an enzyme replacement therapy, such as for the treatment of bone mineralization disorders, e.g., hypophosphoesterase (HPP). The methods include diagnosing the subject for the presence of a neutralizing antibody that affects the efficacy of the treatment, administering a treatment suitable for reducing the deleterious effects of the neutralizing antibody, and continuing an alkaline phosphatase treatment.
Owner:ALEXION PHARMACEUTICALS INC

Application of flavin monooxygenase 3 inhibitor in preparation of medicine for preventing and / or treating acute pancreatitis

The invention provides application of a flavin monooxygenase 3 inhibitor in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of medicines. The flavin monooxygenase 3 inhibitor is methimazole or a pharmaceutically acceptable salt, a prodrug or a derivative of methimazole. Experimental results show that after the methimazole is orally taken, the nidus area of animal pancreatitis is obviously reduced, the pathological score is obviously improved, the in-vivo inflammation level is obviously inhibited, and the blood amylase and lipase levels are obviously reduced; the levels of pancreatitis factors and chemotactic factors are reduced, and the oxidative stress index is reduced. In addition, by combining methimazole with the traditional Chinese medicine monomer for inhibiting the trimethylamine oxide level, the curative effect is better. Compared with the prior art, the application has the advantages that the core regulation effect of the trimethylamine oxide in the pathological process of the acute pancreatitis is disclosed for the first time, the limitation of the traditional anti-inflammatory or enzyme replacement therapy is broken through, and the acute pancreatitis is treated by inhibiting the trimethylamine oxide level by inhibiting the flavin monooxygenase 3.
Owner:FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV

IONIZABLE LIPID NANOPARTICLES FOR IN UTERO mRNA DELIVERY

Disclosed herein is a method for the delivery of prenatal therapeutics, enzyme replacement therapy, or gene therapy to a fetus in need thereof. The method comprises introducing ionizable lipid nanoparticles (LNPs) nanoparticles comprising a therapeutic mRNA composition into the circulation of the fetus in need of treatment such that the ionizable LNPs deliver the therapeutic mRNA composition.
Owner:PERANTEAU WILLIAM

Pharmaceutical compositions containing heparan N-sulfatase with improved stability

The present invention relates to a pharmaceutical composition for CNS delivery of high-concentration heparan N-sulfatase (HNS) with improved stability, and a pharmaceutical dosage form containing the same. The pharmaceutical composition and pharmaceutical dosage form containing the same according to the present invention have excellent dosage form stability, such as reduced turbidity and significantly improved purity, and are therefore useful in enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis type III.
Owner:GC BIOPHARMA CORP

Purified arylsulfatase a and compositions thereof

InactiveEP4545141A2Nervous disorderPeptide/protein ingredientsWhite blood cellMetachromatic leucodystrophy
The present invention provides, among other things, methods of treatment of Metachromatic Leukodystrophy Disease (MLD) and compositions comprising recombinant arylsulfatase A (ASA) protein using enzyme replacement therapy.
Owner:TAKEDA PHARMA CO LTD

Therapeutic adeno-associated viruses for treatment of pompe disease with long-term stop of GAA enzyme replacement therapy

Disclosed herein are methods for treating Pincare Disease comprising administering a recombinant AAV (rAAV) vector comprising an rAVV genome comprising a heterologous nucleic acid encoding an acidic alpha-glucosidase (GAA) polypeptide operably linked to a liver-specific promoter wherein enzyme replacement therapy (ERT) is withdrawn or not administered to a subject.
Owner:ASKBIO INC +1

Compositions for treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS)

PendingCN122121891AOrganic active ingredientsNervous disorderSanfilippo syndrome type aPharmaceutical drug
The present invention relates to a pharmaceutical composition for preventing or treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS), and more particularly, to an optimal dose and period of administration of heparan N-sulfatase, which can effectively reduce the accumulation of heparan sulfate (HS) while improving the cognition of patients. According to the present invention, it can be used as enzyme replacement therapy (ERT) for treating Sanfilippo syndrome type A.
Owner:KOREA GREEN CROSS CORP

Purified arylsulfatase A and compositions thereof

The present invention provides, inter alia, methods of treating metachromatic white matter dystrophy disease (MLD) and compositions comprising a recombinant arylsulfatase A (ASA) protein using enzyme replacement therapy.
Owner:TAKEDA PHARMA CO LTD

Marker for acid sphingomyelinase disorders and uses thereof

ActiveUS20240398907A1Peptide/protein ingredientsHydrolasesBiochemistryAcid sphingomyelinase
The present disclosure provides methods of screening, diagnosing, monitoring and / or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and / or treatment of an ASM disorder, for example using enzyme replacement therapy.
Owner:GENZYME CORP

Biomarkers For Lysosomal Storage Diseases

Methods of determining a disease score of a patient diagnosed with lysosomal storage disease (LSD) are described. The disease score includes one or more of the following: (i) one or more biofluid biomarkers; (ii) one or more neurophysiological measurements; and (iii) one or more neurobehavior measurement. Also described method of treating LSD including determining the disease score and administering to the patient a therapy. The therapy includes one or more of the following: (i) enzyme replacement therapy, (ii) gene therapy; and (iii) a small molecule.
Owner:AMICUS THERAPEUTICS INC +1

Compositions and methods for treatment of homocystinuria

Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO

Cystathionine beta-synthase for the treatment of homocystinuria

The present invention relates to cystathionine beta-synthase for treating homocystinuria. The present invention provides reagents and methods for enzyme replacement therapy using human cystathionine beta-synthase (CBS), homologs, variants or mutants thereof to treat homocystinuria and other related diseases and conditions.
Owner:COLORADO UNIV SENATE

Compositions and methods for treatment of homocystinuria

Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO

Compositions comprising iduronate-2-sulfatase

The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
Owner:TAKEDA PHARMA CO LTD

Pharmaceutical composition comprising heparan n-sulfatase with improved stability

The present invention relates to a high concentration heparan N-sulfatase (HNS) pharmaceutical composition with enhanced stability for CNS delivery and a pharmaceutical formulation comprising the same. The pharmaceutical composition and the pharmaceutical formulation comprising the same according to the present invention have excellent formulation stability, such as reduction of turbidity and significant improvement of purity, which can be used in enzyme replacement therapy (ERT) for the treatment of type III mucopolysaccharide storage disease.
Owner:KOREA GREEN CROSS CORP

Fusion proteins comprising enzyme replacement therapy enzymes

The present invention relates to fusion proteins comprising an enzyme replacement therapy enzyme, and provides fusion proteins comprising an enzyme replacement therapy enzyme and an Fc region, and methods of using such proteins to treat lysosomal storage disorders. Also provided herein are methods of delivering an agent across the blood-brain barrier.
Owner:DENALI THERAPEUTICS INC

Methods for treating symptoms and disorders associated with lysosomal storage diseases

This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy. This includes pain, such as abdominal pain, and dermatological disorders, such as angiokeratoma, in a patient having a disease such as Fabry disease. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods.
Owner:GENZYME CORP

Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase

The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
Owner:TAKEDA PHARMA CO LTD

Cystathionine beta-synthase for treatment of homocystinuria

The present invention relates to cystathionine beta-synthases for use in the treatment of homocystinuria. The present invention provides agents and methods for enzyme replacement therapy using human cystathionine beta-synthase (CBS), homologs, variants, or mutants thereof to treat homocystinuria and other related diseases and disorders.
Owner:COLORADO UNIV SENATE

Methods for purification of arylsulfatase A

The present invention provides, among other things, improved methods for purifying arylsulfatase A (ASA) protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant ASA protein can be purified from unprocessed biological materials, such as, ASA-containing cell culture medium, using a process involving as few as four chromatography columns and only one step of post-chromatographic ultrafiltration / diafiltration.
Owner:TAKEDA PHARMA CO LTD

Method for purifying aryl sulfatase A

The present invention provides, inter alia, improved methods for purifying arylsulfatase A (ASA) proteins that are recombinantly produced for enzyme replacement therapy. The present invention is based, in part, on the surprising discovery that recombinant ASA proteins can be purified from untreated biological materials (e.g., ASA-containing cell culture media) using processes that include only four chromatographic columns and only one step of post-chromatographic column ultrafiltration / diafiltration.
Owner:TAKEDA PHARMA CO LTD

Compositions and methods for treatment of homocystinuria

Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO